Cat. No. 3236
Biological ActivityPotent and competitive pituitary adenylate cyclase-activating polypeptide receptor (PAC)1 antagonist (IC50 = 2 nM). Inhibits PACAP(1-27)-induced stimulation of adenylate cyclase (Ki = 1.5 nM). Antitumor activity in vivo.
(Modifications: Lys-33 = C-terminal amide)
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Robberecht et al (1992) Structural requirements for the occupancy of pituitary adenylate-cyclase-activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes. Discovery of PACAP(6-38) as a potent antagonist. Eur.J.Biochem. 207 239. PMID: 1321043.
Leyton et al (1998) PACAP(6-38) inhibits growth of prostate cancer cells. Cancer Lett. 125 131. PMID: 9566707.
Kojro et al (2006) The neuropeptide PACAP promotes a-secretase pathway for processing Alzheimer amyloid precursor protein. FASEB J. 20 512. PMID: 16401644.
If you know of a relevant citation for this product please let us know.
Keywords: PACAP 6-38, supplier, Potent, PAC1, receptors, antagonists, Pituitary, Adenylate, Cyclase, Activating, Peptide, PACAP638
Find multiple products by catalog number
New Products in this Area
Potent neuropeptide S receptor (NPSR) antagonistTC OT 39
Nonpeptide oxytocin and V2 receptor partial agonist; also a V1a receptor antagonistTolvaptan
Potent and selective vasopressin V2 receptor antagonist; renoprotective and orally activeML 00253764 hydrochloride
Melanocortin MC4 receptor antagonist; brain penetrantGSK 1562590 hydrochloride
High affinity, selective urotensin II (UT) receptor antagonistMA 2029
Potent and selective, competitive motilin receptor antagonist; orally active
October 5 - 8, 2014